Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/11/2025

Antithrombotic Therapy in CAD and TIA

Antiplatelet Therapy

  • The European Society of Cardiology recommends aspirin 75-100 mg daily lifelong in patients with CAD who have experienced a TIA 1, 2
  • Clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin monotherapy in patients with CAD and TIA 1, 2
  • The European Society of Cardiology suggests that clopidogrel 75 mg daily may be considered in preference to aspirin in patients with a history of ischemic stroke or TIA, though this is a weaker recommendation 1
  • After recent PCI-stenting in CAD patients, DAPT with aspirin 75-100 mg plus clopidogrel 75 mg daily for up to 6 months is recommended as the default strategy 1, 2
  • DAPT duration may be shortened to 1-3 months in patients at very high bleeding risk after PCI 1

Oral Anticoagulation

  • When OAC is initiated in a patient with AF, a DOAC is recommended in preference to warfarin by the European Society of Cardiology 1, 2
  • Long-term OAC therapy is recommended in patients with AF and CHA2DS2-VASc score ≥2 in males and ≥3 in females 1
  • For patients with TIA, anticoagulation can be started one day after the event, but this recommendation is from Praxis Medical Insights and may not be preferred 4
  • Anticoagulation should not be started too early (less than 48 hours) after ischemic stroke as it may increase intracranial bleeding risk, however this is also from Praxis Medical Insights 4

Combination Therapy

  • The European Society of Cardiology recommends a stepwise approach for combination therapy with OAC plus antiplatelet after PCI in patients requiring OAC 1, 2
  • Initial triple therapy (OAC + aspirin + clopidogrel) is recommended immediately after PCI, followed by early cessation of aspirin (≤1 week) after uncomplicated PCI 1, 2
  • Continuation of OAC plus clopidogrel is recommended up to 6 months in patients not at high ischemic risk and up to 12 months in patients at high ischemic risk 2
  • Ticagrelor or prasugrel are generally not recommended as part of triple antithrombotic therapy with aspirin and OAC by the European Society of Cardiology 2
  • A proton pump inhibitor is recommended in patients at increased risk of gastrointestinal bleeding for the duration of combined antithrombotic therapy 2

Special Considerations

  • Oral anticoagulation (INR 2.0-3.0) for at least 3 months and up to 1 year is reasonable in patients with acute MI and LV thrombus, according to the American Heart Association 5, 6
  • Aspirin should be used concurrently in doses up to 162 mg/day (preferably enteric-coated) during oral anticoagulant therapy 5, 6
  • The maintenance dose of aspirin should be 75-100 mg daily when used with DAPT or OAC to minimize bleeding risk while maintaining efficacy, as recommended by the European Society of Cardiology 1, 2, 8